Lantern Pharma
LTRNLTRN · Stock Price
Historical price data
Overview
Lantern Pharma is an AI-driven oncology company using its RADR® platform to streamline drug discovery and clinical development. The company has advanced a pipeline to Phase 2, focusing on biomarker-stratified patient populations to improve success rates and reduce costs. Its strategy centers on leveraging massive datasets and machine learning to reposition drug candidates and design more efficient clinical trials. Key achievements include building a significant data asset, advancing multiple programs into the clinic, and securing orphan drug designations.
Technology Platform
RADR® is a proprietary AI/ML platform integrating ~200 billion oncology data points and over 200 algorithms to de-risk drug development by clarifying MoA, prioritizing indications, predicting combinations, and stratifying patients.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Tavocept(BNP7787) in combination with cisplatin and either d... | Non-small Cell Lung Cancer | Phase 3 | |
| BNP7787 + Placebo | Breast Neoplasms | Phase 3 | |
| Irofulven | Metastatic Castration-Resistant Prostate Cancer Patients | Phase 2 | |
| LP-300 + Pemetrexed + Carboplatin | Adenocarcinoma of Lung | Phase 2 | |
| LP-184 + Spironolactone + Olaparib | Advanced Solid Tumor | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
Competes in both AI drug discovery (vs. Recursion, Exscientia) and targeted oncology therapeutics. Differentiation lies in RADR®'s exclusive oncology focus and massive dataset. Competitive edge is using AI to identify precise patient populations for its molecules rather than just discovering novel chemistry.